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Abstract
Objective
TP53, a well-known tumor-suppressor gene in bladder carcinogenesis, has a functional sin-
gle-nucleotide polymorphism on codon 72. The aim of this study was to elucidate the associ-
ation between TP53 codon 72 polymorphism and somatic mutations in bladder cancer.
Material and methods
Germline TP53 codon 72 polymorphism and somatic mutations of 50 cancer-associated
genes were analyzed in 103 bladder cancer patients (59 non-muscle-invasive and 44 mus-
cle-invasive), using Taqman genotyping assay and target sequencing, respectively. The
expression of FGF-FGFR signaling pathway genes was analyzed by RNA sequencing of
frozen tissue.
Results
The allele frequency of TP53 codon 72 in our cohort was 37, 42, and 21% for Arg/Arg, Arg/
Pro, and Pro/Pro, respectively. Interestingly, the prevalence of FGFR3 mutation was higher
in patients with the Arg allele, whereas that of the RAS mutation was higher in patients with-
out the Arg allele. The same association was seen in non-muscle-invasive bladder cancer
(NMIBC) patients and no differences were observed in muscle-invasive bladder cancer
patients. In NMIBC, FGFR1 expression was higher in patients without the Arg allele and
FGFR3 expression was higher in patients with the Arg allele.
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Conclusion
The germline TP53 codon 72 polymorphism was associated with mutations of FGFR3 or
RAS and expression of FGFR1 and FGFR3 in NMIBC. These findings provide new insight
into the molecular mechanisms underlying the influence of the genetic background on carci-
nogenesis in bladder cancer.
Introduction
Bladder cancer is the fourth and twelfth most common malignancy in men and women,
respectively [1]. It is particularly common in the elderly and male population. Cigarette smok-
ing and some Chinese herbs are well-known risk factors [2–5]. Bladder cancer is derived from
urothelium and progresses from non-muscle-invasive bladder cancer (NMIBC) to muscle-
invasive bladder cancer (MIBC), before becoming metastatic. About 70% of bladder cancer
patients have NMIBC, and the remaining 30% have MIBC or metastatic disease [6]. Molecular
and histopathological features suggest that bladder cancer can develop along at least two dis-
tinct pathways. In one pathway, the papillary NMIBC develop via epithelial hyperplasia and
recruitment of branching vasculature, and in the other pathway MIBC develops via flat dyspla-
sia and carcinoma in situ (CIS) [2, 7]. Several important driver genes or tumor suppressor
genes involved in carcinogenesis of bladder urothelium have been identified. For example,
TP53 mutations are key drivers for CIS or MIBC [8]. On the other hand, NMIBC is character-
ized by activating point mutations in FGFR3 or RAS [9, 10], and, interestingly, activating RAS
mutations are mutually exclusive with FGFR3 mutations [10]. However, the underlying mech-
anism controlling the selection of specific somatic mutations in bladder cancer remains
unknown.
TP53 functions as a transcription factor, regulating the expression of several downstream
genes, resulting in cell cycle arrest and apoptosis [11]. TP53 is also known to have a functional
single-nucleotide polymorphism (SNP) in codon 72 (rs1042522), which results in the substitu-
tion of proline (Pro) for arginine (Arg) in the proline-rich domain. TP53 Arg72 is more potent
in apoptosis induction, whereas TP53 Pro72 is better in inducing cell cycle arrest and DNA
damage repair [12–15]. TP53 codon 72 polymorphism has been linked to an increased risk of
breast cancer, cervical cancer, esophageal cancer, gastric cancer, lung cancer, and skin cancer
[16]. However, studies relating to the association between TP53 codon 72 polymorphism and
bladder cancer susceptibility have shown inconclusive results [16]. We previously reported
that this polymorphism affects the phenotypes or clinical outcomes of bladder cancer [17], but
the underlying mechanism remains unknown.
Recently, several studies reported the interesting finding that germline SNPs affect specific
somatic mutations. For instance, MC1R polymorphism affects BRAF mutant melanoma [18,
19], a JAK2 germline polymorphism affects JAK2 V617F mutant myeloproliferative neoplasms
[20, 21], and TACC3 polymorphism affects FGFR3 mutant bladder cancer [22]. Some reports
showed that the TP53 Pro allele is associated with an increased frequency of TP53 mutations
in non-small cell lung cancer (NSCLC) [23, 24]. However, there is no report around the rela-
tionship between TP53 codon 72 polymorphism and somatic mutations in bladder cancer.
We hypothesized that TP53 codon 72 polymorphism could affect somatic mutations during
bladder carcinogenesis and conducted this study to compare germline TP53 codon 72 poly-
morphism and somatic mutations in bladder cancer. In our cohort, there was no relationship
between TP53 codon 72 polymorphism and TP53 mutation. However, mutually exclusive
Association of TP53 polymorphism with somatic mutations in bladder cancer
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mutations of FGFR3 and RAS in NMIBC were significantly related with the TP53 codon 72
polymorphism. This finding provides new insight into the relationship between host germline
polymorphism and selection for somatic mutation type in bladder carcinogenesis.
Materials and methods
Patients and tissue samples
This prospective multicenter cohort study included 144 patients with clinical diagnosis of
urothelial carcinoma from seven institutions [25]. The research protocol was approved by the
Ethics Committee of Tsukuba University Hospital (Approval number: H25-116). It was also
reviewed and approved by the Ethics Committees of the following institutes: Tohoku Univer-
sity Hospital, Akita University Hospital, Kyoto University Hospital, Kagawa University Hospi-
tal, Hitachi General Hospital, and Tsukuba Medical Center Hospital. Tumor specimens,
blood, and clinicopathological information were collected with written informed consent.
Primary bladder cancer tissue samples from 103 patients were stored as formalin-fixed par-
affin embedded (FFPE) and frozen tissue. All tissue sections included malignant tumor cell
nuclei in 10% or more cells of the whole specimen. The remaining 41 patients were excluded
because their tumors originated in the upper urinary tract origin, were without urothelial his-
tology, or fresh frozen tissue could not be obtained.
Hematoxylin and eosin staining was performed, and the slides were evaluated by patholo-
gists at each institute. Tumors were staged according to the 2009 Union for International Can-
cer Control (UICC) 7th tumor-nodes-metastasis (TNM) classification system.
Tumor DNA extraction from FFPE samples and mutation analysis
Tumor DNA from FFPE was extracted using a QIAamp DNA FFPE Tissue Kit (QIAGEN, Hil-
den, Limburg, Germany) according to the manufacturer’s instructions. The DNA concentra-
tion was assessed using a Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA, USA).
Tumor DNA with more than 1.5 ng/μL, according to the Qubit fluorometer, was subjected to
further analysis. In total, 10 ng DNA was used as template to generate an amplicon library for
sequencing. Libraries were prepared using an Ion AmpliSeq Library Kit 2.0 and an Ion Ampli-
Seq Cancer Hotspot Panel v2 (Life Technologies, Waltham, MA, USA), which amplifies 207
amplicons covering approximately 2800 COSMIC mutations in the following 50 cancer-asso-
ciated genes in alphabetical order: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A,
CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3,
FRBB4, GNA11, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET,
MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET,
SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL. Adapter ligation, nick repair, and poly-
merase chain reaction (PCR) amplification were performed according to the manufacturer’s
instructions. Emulsion PCR and enrichment steps were carried out using an Ion OneTouch
Template Kit and an Ion OneTouch system (Life Technologies), according to the manufac-
turer’s instructions. Following enrichment, the amplicon libraries were sequenced with an Ion
PGM Sequencer (Life Technologies). For data analysis, Torrent Suite 4.0.2 was used, and
mutations were detected by the Variant Caller plugin 4.0–6 with somatic/high stringency con-
figuration provided by Ion Torrent (Thermo Fisher Scientific).
Germline DNA extraction and TP53 codon 72 genotyping
Germline DNA was extracted from peripheral blood using the DNeasy Blood and Tissue Kit
(QIAGEN) according to the manufacturer’s instructions. Germline DNA samples were
Association of TP53 polymorphism with somatic mutations in bladder cancer
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genotyped using TaqMan single-nucleotide polymorphism genotyping assays for rs1042522
(Applied Biosystems, Waltham, MA, USA) according to the manufacturer’s instructions. The
results were analyzed on a 7500 real-time PCR system using the allelic discrimination assay
program of Sequence Detection software version 1.3 (Applied Biosystems).
RNA extraction and sequence analysis
Total RNA was extracted from frozen tissue using TRIzol (Thermo Fisher Scientific), prepared
into messenger RNA (mRNA) libraries, and sequenced using Illumina NextSeq 500. Quality
control, ambiguity and length trimming, mapping to the reference genome, normalization of
gene expression, and evaluation of differential gene expression were performed using CLC
Genomics Workbench version 10 (Qiagen). Default settings were used for quality control and
ambiguity and length trimming. RNA-sequence reads were aligned to the reference genome of
Homo sapiens GRCh38.p10 (GenBank accession number GCA_000001405.25).
Statistical analysis
Differences were assessed using Kruskal-Wallis test and Mann-Whitney U test with Bonfer-
roni correction. The chi-square test was used to evaluate associations between categorical vari-
ables. When the p-value was p< 0.05 with chi-square test, residual analysis was performed to
identify which category was significant. Gene expression was normalized using transcript per
million. Wald test with Benjamini-Hochberg multiple test correction was used for evaluation
of differential gene expression. Genes with false discovery rate adjusted p-values< 0.05 were
considered differentially expressed. Adjusted residuals were calculated with js-STAR ver 9.1.7
[26], evaluation of differential gene expression was performed using CLC Genomics Work-
bench version 10 (Qiagen), and the other statistical analyses were performed using STAT view
ver5.0 (SAS Institute Inc. Cary, NC, USA).
Results
Association between germline TP53 codon 72 polymorphism and somatic
mutations in bladder cancer
Mutation analysis showed that FGFR3, TP53, PIK3CA, RAS (HRAS, KRAS, or NRAS), AKT1,
CTNNB1, ATM, BRAF, and RB1 mutations were present in at least one or more patients (Fig 1
and S1 Table). There were no mutations in the remaining 39 genes. The prevalence of FGFR3
mutation was 33%, followed by TP53 (29%), PIK3CA (25%), and RAS (24%) mutation. FGFR3
mutation was mutually exclusive with RAS mutation (p< 0.01; RAS mutation included HRAS,
KRAS, and NRAS) and TP53 mutation (p = 0.02), but co-existent with PIK3CA mutation
(p< 0.01). TP53 mutation and RAS mutation were also exclusive (p< 0.01). Other mutations
were not correlated with each other. The prevalence of mutations in FGFR3 or RAS was higher
in NMIBC than in MIBC (FGFR3 was 51% and 25%, while RAS was 27% and 9.4% in NMIBC
and MIBC, respectively).
Table 1 shows the frequencies of TP53 codon 72 polymorphism. Three genotypes, Arg/Arg,
Arg/Pro, and Pro/Pro, were found in 37% (38/103), 42% (43/103), and 21% (22/103) of the
patients, respectively. The results fit the Hardy-Weinberg equilibrium. As shown in Table 1,
clinical characteristics, including tumor grade, tumor stage, or smoking status, were not signif-
icantly different among the patients. In contrast, there was a significant difference in the preva-
lence of mutations in FGFR3 and PIK3CA (p< 0.01 and p = 0.04, respectively) among TP53
codon 72 polymorphisms but not in RAS and TP53. Patients with Pro/Pro had significantly
Association of TP53 polymorphism with somatic mutations in bladder cancer
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lower FGFR3 mutation rates and patients with Arg/Arg had higher PIK3CA mutation rates, as
evaluated with adjusted residuals.
Influence of Arg allele of TP53 codon 72 polymorphism on FGFR3 or RAS
mutations in NMIBC
We further analyzed the allele of TP53 polymorphism related to the prevalence of somatic
mutations in bladder cancer-related genes (Table 2). When both NMIBC and MIBC patients
were analyzed and divided into two groups as having Arg allele (Arg/Arg or Arg/Pro) and not
having Arg allele (Pro/Pro), the prevalence of mutations in FGFR3 was significantly higher in
patients with the Arg allele (41% vs 4.5%, p< 0.01). In contrast, the prevalence of mutations in
RAS was higher in patients without the Arg allele (41% vs 20%, p = 0.04). The prevalence of
Fig 1. The frequency of somatic mutations. Upper half shows the results of NMIBC patients, and lower half shows that of MIBC patients. We analyzed 50 cancer-
related genes with Ion Ampli Seq Cancer Hotspot Panel v2 and listed the genes with mutations. Each horizontal column indicates a patient. Grey columns indicate the
presence of mutation.
https://doi.org/10.1371/journal.pone.0220173.g001
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mutations in PIK3CA and TP53 was not different between these two groups. When the
patients were stratified into groups as having Pro allele (Pro/Pro or Arg/Pro) and not having
Pro allele (Arg/Arg), only the prevalence of mutations in PIK3CA was higher in patients with-
out the Pro allele (39% vs 17%, p = 0.01).
Table 1. Patient characteristics and prevalence of somatic mutations with respect to the TP53 codon 72 polymorphism.
Total, n Arg/Arg
n (%)
Arg/Pro
n (%)
Pro/Pro
n (%)
p-value
TP53 codon 72 polymorphism 103 38 (37) 43 (42) 22 (21)
Age Median 71 67 73 71 0.24��
(year) (range) (39–87) (41–86) (39–87) (60–87)
Sex male 85 34 (86) 33 (77) 18 (82) 0.32���
female 18 4 (14) 10 (23) 4 (18)
Clinical NMIBC(≦T1) 59 21 (55) 28 (65) 10 (45) 0.30���
Stage MIBC(≧T2) 44 17 (45) 15 (35) 12 (55)
Grade Low 33 12 (32) 16 (37) 5 (23) 0.49���
High 70 26 (68) 27 (63) 17 (77)
Smoking non-smoker 34 11 (30) 15 (35) 8 (36) 0.81���
status smoker 62 24 (63) 24 (56) 14 (64)
unknown 7 3 (8) 4 (9) 0
Somatic FGFR3 34 16 (42) 17 (40) 1 (4.5) < 0.01���
mutation RAS� 25 10 (26) 6 (14) 9 (41) 0.053���
PIK3CA 26 15 (39) 8 (19) 3 (14) 0.04���
TP53 30 9 (24) 15 (35) 6 (27) 0.53���
�RAS: KRAS/HRAS/NRAS
��: Kruskal-Wallis test
���: chi-square test
https://doi.org/10.1371/journal.pone.0220173.t001
Table 2. Frequency of somatic mutations divided according to the clinical stage in TP53 codon 72 polymorphism.
TP53 codon72 polymorphism
Somatic Mutation with Arg allele, n (%) without Arg allele, n (%) p�� value without Pro allele, n (%) with Pro allele, n(%) p�� value
All cases N 81 22 38 65
FGFR3 33 (41) 1 (4.5) < 0.01 16 (42) 18 (28) 0.13
RAS� 16 (20) 9 (41) 0.04 10 (26) 15 (23) 0.71
PIK3CA 23 (28) 3 (14) 0.16 15 (39) 11 (17) 0.01
TP53 24 (30) 6 (27) 0.83 9 (24) 21 (32) 0.35
NMIBC n 49 10 21 38
FGFR3 25 (51) 1 (10) 0.02 11 (52) 15 (19) 0.34
RAS� 13 (27) 7 (70) < 0.01 7 (33) 13 (34) 0.95
PIK3CA 13 (27) 1 (10) 0.26 8 (38) 6 (16) 0.054
TP53 7 (14) 1 (10) 0.72 1 (4.8) 7 (18) 0.14
MIBC n 32 12 17 27
FGFR3 8 (25) 0 (0) 0.06 5 (29) 3 (11) 0.13
RAS� 3 (9.4) 2 (17) 0.50 3 (18) 2 (7.4) 0.30
PIK3CA 10 (31) 2 (17) 0.33 7 (41) 5 (19) 0.10
TP53 17 (53) 5 (42) 0.50 8 (47) 14 (52) 0.76
�RAS: KRAS/HRAS/NRAS
��: chi-square test
https://doi.org/10.1371/journal.pone.0220173.t002
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Because mutations in FGFR3 and RAS were more frequently detected in NMIBC, the preva-
lence of TP53 codon 72 polymorphism and somatic mutations were separately analyzed in
NMIBC and MIBC. In NMIBC, the prevalence of mutations in FGFR3 was higher in patients
with the Arg allele (51% vs 10%, p = 0.02) and the prevalence of RAS mutation was significantly
higher in patients without the Arg allele (70% vs 27%, p< 0.01). In MIBC, no significant dif-
ferences were identified between TP53 codon 72 polymorphism and somatic mutations.
TP53 codon 72 polymorphism could affect the expression of FGFR1 and
FGFR3
Since fibroblast growth factor (FGF)-FGF receptor (FGFR) signaling pathways are activated
not only through FGFR gene mutation, but also with overexpression of FGF-FGFR related
genes [2], the expression of all 22 subclasses of FGF (FGF1-FGF14, FGF16-FGF23) and four
subclasses of FGFR (FGFR1-FGFR4) was determined. The association of TP53 codon 72 poly-
morphism with the expression of these genes was analyzed (S2 Table). Significant differences
in the expression of FGFR1 and FGFR3 (p = 0.02 and p = 0.04, respectively) were observed,
with no significant difference in the expression of other FGFs and FGFRs (S3 Table). In detail,
comparing patients with Arg/Pro vs Pro/Pro, FGFR1 expression was significantly higher in
patients with Pro/Pro, and FGFR3 expression was higher in patients with Arg/Pro (p� = 0.010
and p� = 0.015, respectively). Comparing patients with Arg/Arg vs Pro/Pro, FGFR1 expression
tended to be higher in patients with Pro/Pro, FGFR3 expression was not significantly different
(p� = 0.020 and p� = 0.38, respectively). Comparing patients with Arg/Arg vs Arg/Pro, neither
FGFR1 nor FGFR3 was significantly different (p� = 0.73 and p� = 0.64, respectively). �: p-value
was evaluated with Mann-Whitney’s U test with Bonferroni correction.
We further analyzed the allele of TP53 polymorphisms related to the expression of FGFR1
and FGFR3. As shown in Table 3, when both NMIBC and MIBC patients were analyzed,
FGFR3 expression was higher in patients with the Arg allele (FDR-p = 0.02). In NMIBC
patients, FGFR3 expression was higher in patients with the Arg allele (FDR-p = 0.02). FGFR1
expression was higher in patients without the Arg allele (FDR-p< 0.01). However, in MIBC
patients, no significant differences were identified between TP53 codon 72 polymorphism and
expression of FGFRs.
Table 3. FGFR1/3 mRNA expression with respect to the TP53 codon 72 polymorphism.
FGFR1 expression FGFR3 expression
Clinical stage TP53 codon72 polymorphism total, n mean +/- SD FDR-p� value mean +/- SD FDR-p� value
All cases with Arg allele 81 1.18 +/- 8.11 0.14 82.85 +/- 128.78 0.02
without Arg allele 22 2.84 +/- 8.64 35.66 +/- 77.39
without Pro allele 38 1.28 +/- 8.99 0.66 63.36 +/- 97.28 1
with Pro allele 65 1.29 +/- 7.91 54.14 +/- 135.48
NMIBC with Arg allele 49 0.90 +/- 2.17 < 0.01 120.07 +/- 144.98 0.02
without Arg allele 10 2.05 +/- 2.50 50.83 +/- 28.21
without Pro allele 21 0.90 +/- 2.32 0.79 152.85 +/- 107.17 1
with Pro allele 38 1.01 +/- 2.25 79.26 +/- 100.57
MIBC with Arg allele 32 2.10 +/- 12.26 1 40.01 +/- 83.26 1
without Arg allele 12 4.33 +/- 10.67 21.36 +/- 103.68
without Pro allele 17 1.90 +/- 13.11 1 34.67 +/- 79.68 1
with Pro allele 27 3.26 +/- 11.15 25.71 +/- 94.50
�: Wald test with Benjamini-Hochberg multiple test correction
https://doi.org/10.1371/journal.pone.0220173.t003
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Combination of smoking status and TP53 codon 72 polymorphism could
affect somatic mutations in NMIBC
Since smoking status has been associated with somatic mutation [27], we analyzed the fre-
quency of FGFR3 or RAS mutations in TP53 codon 72 polymorphism and smoking status.
Among NMIBC patients with the Arg allele, the prevalence of RAS mutation was significantly
higher in smokers than in non-smokers (34% (10/29) vs 6.7% (1/15), p = 0.04). In contrast,
among NMIBC patients without the Arg allele, there was no significant difference between the
prevalence of RAS mutations and smoking status (smokers 71% (5/7) and non-smokers 67%
(2/3); p = 0.88, Fig 2). There was no significant association between smoking status and FGFR3
or RAS mutations in TP53 codon 72 polymorphism among MIBC patients.
Discussion
In this study, we show that germline TP53 codon 72 polymorphism could affect FGFR3 and
RAS mutations in NMIBC. Although there are some reports on the association between TP53
codon 72 polymorphism and TP53 mutation in NSCLC [23, 24], to our knowledge, there is no
report on the relationship between TP53 codon 72 polymorphism and somatic mutations,
other than TP53 mutation. In our dataset, no association between TP53 mutation and TP53
codon 72 polymorphism was observed (Tables 1 and 2). However, patients with the Arg allele
were associated with FGFR3 mutation and patients without the Arg allele were associated with
RAS mutation in NMIBC (Table 2). To the best of our knowledge, this is the first report clarify-
ing the relationship between germline TP53 codon 72 polymorphism and somatic mutations
in bladder cancer. Several studies have identified that germline polymorphisms are associated
with specific somatic mutations [18–22]. Our results also imply that germline background
could affect the specific somatic mutations in bladder cancer.
Fig 2. Prevalence of mutations in FGFR3 and RAS in TP53 codon 72 polymorphism and smoking status of NMIBC patients. Black
bar and gray bar indicate the frequencies of FGFR3 and RAS mutation, respectively. The number in parentheses indicates the patients’
number.
https://doi.org/10.1371/journal.pone.0220173.g002
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The FGF-FGFR signaling pathway is composed of several subtypes of FGFs and FGFRs.
Some studies have focused on activating FGFR1 and FGFR3 in bladder cancer [28, 29]; how-
ever, other FGFRs and FGF-ligands were not studied. Although the activation and overexpres-
sion of FGFR3 have been reported [30], the relationship between other FGF-FGFR subtypes
and their expression status have not been documented. We show that the TP53 codon 72 poly-
morphism is also associated with the expression of FGFR1 and FGFR3. Expression of FGFR1
was higher in patients without the Arg allele, while expression of FGFR3 was higher in patients
with the Arg allele. Because FGFR3 mutation activates point mutations [2], its expression was
higher in patients with the Arg allele who show higher frequency of the FGFR3 mutation. On
the other hand, the reason for higher expression of FGFR1 in patients without the Arg allele is
unclear. A previous study showed that silencing FGFR1 expression using small interfering
RNA was effective in elevating FGFR3 expression and tumor supportive activity, suggesting
that FGFR1 and FGFR3 have an inverse relationship [31].
Several studies and the cohort presented here show that FGFR3 and RAS mutations are
mutually exclusive events in bladder cancer [10, 27]. The mutual exclusivity of FGFR3 and
RAS gene mutations is thought to reflect activation of the same pathway. The oncogenic role
of activated FGFR3 is mediated by the activation of mitogen-activated protein kinase through
the RAS signaling pathway [32]. FGFR3 mutations are strongly associated with low-grade and
low stage bladder cancer, with lower frequency of recurrence [33]. Unlike FGFR3 mutations,
no relation of RAS mutational pattern with tumor grade and stage has been found [10]. FGFR3
mutation was seen in about 70% and RAS mutation in about 20% of low-grade non-invasive
papillary tumors [27]. However, whether FGFR3 or RAS mutation is selected in NMIBC is
unclear. Our results suggest that TP53 codon 72 polymorphism contributes to the selection of
somatic mutations in NMIBC.
Several environmental or habitual factors, including smoking and inflammation, have been
associated with bladder carcinogenesis. The dataset presented here suggests that smoking sta-
tus could affect the somatic mutations in NMIBC, based on TP53 codon 72 polymorphism. In
patients with the Arg allele, FGFR3 mutation was higher than RAS mutation. When divided
into smoking status, non-smokers with the Arg allele rarely had RAS mutation. On the other
hand, patients without the Arg allele had RAS mutation, regardless of smoking status. Previous
reports show that smoking is associated with somatic mutations. In NSCLC, EGFR mutations
are more frequently found in non-smokers [34, 35]. Unlike EGFR mutations, most KRAS
mutated NSCLC patients are former or current smokers [36–38]. In bladder cancer, a few
studies have examined the association between smoking and somatic mutations. The cancer
genome atlas (TCGA) data shows no statistically significant association between smoking sta-
tus and somatic mutations [39]. Pandith et al. reported that FGFR3 and RAS mutations were
higher in smokers, but no significant association was found [27]. TCGA analyzed only MIBC
patients [39], whereas Pandith et al. analyzed both MIBC and NMIBC patients [27]. These dis-
crepancies were probably due to analysis of different clinical background factors in patients.
Nonetheless, these results suggest that different types of bladder cancer have specific mutations
depending on the TP53 codon 72 polymorphism and smoking status.
Based on the previous bladder carcinogenesis model [7] and our results, we propose a new
carcinogenesis model in NMIBC (Fig 3). FGFR3 and RAS mutation could be affected by the
TP53 codon 72 polymorphism and smoking status in NMIBC. Non-smokers with the Arg
allele show FGFR3 mutation and smokers with the Arg allele show either FGFR3 or RAS muta-
tion. Patients without the Arg allele show RAS mutation regardless of smoking status. More-
over, germline TP53 polymorphisms could affect the expression of FGFR1 and FGFR3 in
NMIBC. FGFR3 expression was higher in patients with the Arg allele, and FGFR1 expression
was higher in patients without the Arg allele. Taken together these results suggest that TP53
Association of TP53 polymorphism with somatic mutations in bladder cancer
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codon 72 polymorphism and smoking status could affect somatic mutations and FGF-FGFR
signaling in bladder carcinogenesis.
Several reports have shown that TP53 codon 72 polymorphism is a response associated
with chemotherapy or radiotherapy [40, 41]. The mechanisms underlying the influence of the
TP53 codon 72 genotype on anticancer treatment response are still unknown. Although our
data show the relationship between TP53 codon 72 polymorphism and mutations in
FGF-FGFR gene expression, our results cannot explain the mechanism or the difference in
treatment response among TP53 codon 72 polymorphism.
Although our study revealed associations between TP53 codon 72 polymorphisms and
somatic mutations in bladder cancer, it was limited by the relatively small sample size. Addi-
tionally, the cohort consisted of Japanese bladder cancer patients only; there is still a lack of clar-
ity in the underlying mechanism, and we could not identify a treatment strategy around the
TP53 codon 72 polymorphism. Therefore, studies involving larger cohorts and other ethnicities
are needed to confirm our results. Nonetheless, our results contribute to the elucidation of the
mechanism of bladder carcinogenesis. Further clarification regarding the relation between blad-
der carcinogenesis and genetic background will aid the development of bladder cancer therapy.
In conclusion, TP53 codon 72 polymorphism is associated with FGFR3 or RAS mutation in
NMIBC, suggesting that host germline could affect the selection for somatic mutation type in
bladder carcinogenesis.
Fig 3. Proposed mechanism of two-pathway model in bladder carcinogenesis considering TP53 polymorphism and smoking status.
https://doi.org/10.1371/journal.pone.0220173.g003
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